TinyGemsBreaks Archive - Page 13 of 121

MondayAug 26, 2024 10:59 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces ‘Landmark Agreement’ Providing Exposure to the UAE, Middle East

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a contract worth approximately $210 million. According to the announcement, Volt Mobility, a leading United Arab Emirates (“UAE”)-based commercial leasing company, has entered into a purchase agreement to acquire 3,000 Class 1 and Class 3 EV cargo vans and trucks over a 16-month period. Mullen will receive an initial $3 million deposit within 60 days and additional payments as the EVs are delivered. The company will begin shipping the first vehicles immediately. Mullen expects to recognize approximately $210 million in revenue over the next 16 months of the…

ThursdayAug 22, 2024 2:02 pm

TinyGemsBreaks – GEMXX Corp. (GEMZ) Expanding Influence in the Global Energy Sector

GEMXX (OTC: GEMZ) recently announced that its collaborator, Latin America Partners (“LEP”), an emerging leader and an independent E&P company involved in exploring significant hydrocarbon reserves in Latin America, has expanded its team. “LEP is guided by Dinesh Kumar Sarraf, the chairman of the board… He leads a team of distinguished energy industry experts who, for decades, have been actively involved in global oil and gas exploration. This team has since expanded following a recent strategic addition. As GEMXX announced in a recent news release, Ali S. Abood has joined the board of Latin Energy Partners. The addition, GEMXX notes,…

ThursdayAug 22, 2024 1:03 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is reporting on 8-week body weight results from its ongoing animal study WEIGHT-A24-1. According to the company, this is the only study carried out anywhere in the world today to evaluate the relative performance of liraglutide processed with DehydraTECH. The results show that DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide. In humans, semaglutide has been shown in other studies to be more than twice as effective at promoting weight loss as liraglutide. Thus, the announcement noted that the continued outperformance of DehydraTECH-liraglutide compared to DehydraTECH-semaglutide is of particular interest. Additionally, the…

WednesdayAug 21, 2024 12:40 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria’s belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control. Additionally, select DehydraTECH-CBD…

WednesdayAug 21, 2024 11:50 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary to Begin Production of All-New Class 4 Commercial Truck in September

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors, its subsidiary, intends to begin production of saleable units of the Bollinger B4 Chassis Cab, an all-new Class 4 commercial EV truck, on September 16, 2024. Bollinger Motors is partnering on production with Roush Industries, which provides contract manufacturing services from its facility in Livonia, Michigan. According to the announcement, deliveries and revenue recognition of the B4 EV truck is expected to begin in October 2024. “We are already experiencing strong momentum in the market from important customers throughout the country,” commented Jim Connelly, chief…

WednesdayAug 21, 2024 11:25 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. “We are pleased to…

TuesdayAug 20, 2024 2:54 pm

TinyGemsBreaks – ECGI Holdings Inc. (ECGI) Says Success of Allon Equestrian Apparel Line at AETA Is ‘Pivotal Moment’

ECGI Holdings (OTC: ECGI), a diversified holding company with a unique portfolio in viticulture, hospitality and luxury fashion, is reporting on the success of its Allon equestrian apparel line during the American Equestrian Trade Association (“AETA”) International trade show, which was held in Dallas. According to the company, the launch, which included a range of show coats, show shirts, breeches, safety vest covers and jewelry, “drew significant attention from key retailers.” The company called the trade show a “pivotal moment” for Allon, noting that the line continues to gain momentum in the highly competitive equestrian market. “The positive feedback we…

TuesdayAug 20, 2024 11:23 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

MondayAug 19, 2024 11:41 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Continues to Expand Presence in Higher Education Sector with New Vehicle Order

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the sale of the Mullen THREE, Class 3 EV box truck uplift to the facilities operations unit at Princeton University. The Mullen THREE is expected to support the unit’s campus operations as well as contribute to its overall sustainability goals, including reaching zero emissions for on-campus university service vehicles. According to the announcement, the Princeton, New Jersey-based unit has selected the Mullen THREE not only for its zero emissions operation but also for overall vehicle versatility. Mullen’s nationally known EV dealer partner, Pritchard EV, fulfilled the vehicle order.…

FridayAug 16, 2024 2:51 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound(R). The objective would be to evaluate whether DehydraTECH-processed tirzepatide,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks